Most London patients go private to access weight loss drugs
The majority of patients in London taking weight loss medications are doing so privately, with slow rollouts meaning only a…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
WHO directs antibiotic development to priority pathogens
The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to…
-
Eli Lilly finds impurity in compounded tirzepatide
Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor…
-
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral…
-
BioNTech co-founders step down to launch new mRNA venture
The co-founders of BioNTech will leave the company to launch a new mRNA-focused entity, amid mounting losses for the vaccine…
-
Novo and Hims & Hers become partners to end legal feud
Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded…
-
GSK sells liver disease drug candidate to Alfasigma for $690m
Alfasigma has agreed to buy the global rights to GSK’s experimental liver disease drug in a deal worth up to…
-
Pharma rings the changes as CEO shake-up continues
Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical…
-
Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production
Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated…
-
FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism
The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for the treatment of…